for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

60.03USD

Change

0.53(+0.89%)

Volume

5,040,697

Today's Range

59.28

 - 

60.06

52 Week Range

57.04

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint In Phase 2/3 Study In Heavily Treatment-Experienced People Living With HIV

Nov 18 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD ANNOUNCES INVESTIGATIONAL LONG-ACTING HIV-1 CAPSID INHIBITOR, LENACAPAVIR, ACHIEVES PRIMARY ENDPOINT IN PHASE 2/3 STUDY IN HEAVILY TREATMENT-EXPERIENCED PEOPLE LIVING WITH HIV.GILEAD SCIENCES INC - CAPELLA TRIAL RESULTS SUPPORT FURTHER STUDY OF LENACAPAVIR IN PEOPLE WITH MULTIDRUG RESISTANT HIV-1 INFECTION WHO ARE FAILING CURRENT TREATMENT REGIMEN.GILEAD SCIENCES - STUDY FOUND THAT 88% OF PARTICIPANTS RECEIVING LENACAPAVIR (N=21/24) EXPERIENCED AT LEAST A 0.5 LOG(10) REDUCTION IN HIV-1 VIRAL LOAD.GILEAD SCIENCES INC - LENACAPAVIR WAS GENERALLY SAFE AND WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS RELATED TO STUDY DRUG OBSERVED.GILEAD SCIENCES INC - LENACAPAVIR GROUP ACHIEVED A STATISTICALLY SIGNIFICANT GREATER MEAN CHANGE IN VIRAL LOAD VERSUS PLACEBO GROUP.GILEAD SCIENCES INC - LOOK FORWARD TO SHARING DATA FROM LONGER-TERM FOLLOW-UP OF CAPELLA STUDY PARTICIPANTS NEXT YEAR.GILEAD SCIENCES INC - LOOK FORWARD TO SUBMITTING FOLLOW UP DATA FOR REGULATORY APPROVAL.

Gilead Sciences Reports Q3 Non-GAAP Earnings Per Share Of $2.11

Oct 28 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $2.11.SEES FY 2020 NON-GAAP EARNINGS PER SHARE $6.25 TO $6.60.Q3 EARNINGS PER SHARE $0.29.Q3 EARNINGS PER SHARE ESTIMATE $1.90 -- REFINITIV IBES DATA.SEES FY PRODUCT SALES OF $23 BILLION TO $23.5 BILLION.TOTAL REVENUES FOR Q3 2020 WERE $6.6 BILLION, UP 17%, COMPARED TO $5.6 BILLION, FOR SAME PERIOD IN 2019.VEKLURY REVENUES WERE $873 MILLION FOR Q3 2020.PRODUCT SALES, EXCLUDING VEKLURY(®) (REMDESIVIR), INCREASED 2% YEAR-OVER-YEAR TO $5.6 BILLION FOR Q3 2020.GAAP RESULTS FOR Q3 2020 INCLUDED ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGES TOTALING $1.2 BILLION.EXPECTS CORE BUSINESS WILL CONTINUE TO GRADUALLY RECOVER IN Q4 2020 AND INTO FIRST HALF OF 2021.EXPECTS THAT COMPANY'S HIV TREATMENT BUSINESS WILL CONTINUE TO REMAIN LARGELY UNAFFECTED.EXPECTS THAT BY Q1 OF 2021, PATIENTS WITH HCV WILL BEGIN TO INITIATE TREATMENT.GILEAD SCIENCES - GAAP RESULTS FOR Q3 2020 INCLUDED $923 MILLION UNREALIZED LOSS FROM CHANGES IN FAIR VALUE OF GILEAD'S EQUITY INVESTMENTS IN GALAPAGOS NV.GILEAD SCIENCES - ACQUISITION OF IMMUNOMEDICS TO IMMEDIATELY CONTRIBUTE TO CO'S REVENUE GROWTH, EXPECTED TO BE NEUTRAL TO ACCRETIVE TO 2023 NON-GAAP EPS.Q3 2020 REVENUES REFLECT CONTINUED IMPACT FROM COVID-19 PANDEMIC ON HCV AND PRE-EXPOSURE PROPHYLAXIS.CONTINUED TO SEE SIGNS OF RECOVERY IN EUROPE AND UNITED STATES DURING Q3 2020.

Gilead Sciences Says FDA Approved Antiviral Veklury (Remdesivir) For COVID-19

Oct 22 (Reuters) - Gilead Sciences Inc <GILD.O>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES GILEAD’S ANTIVIRAL VEKLURY® (REMDESIVIR) FOR TREATMENT OF COVID-19.GILEAD SCIENCES - USE OF VEKLURY IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE OR WEIGHING LESS THAN 40 KG HAS NOT BEEN APPROVED BY FDA.GILEAD SCIENCES - IN U.S., VEKLURY IS INDICATED FOR PATIENTS FOR TREATMENT OF COVID-19 REQUIRING HOSPITALIZATION.GILEAD SCIENCES - FDA ISSUED A NEW EUA FOR USE OF VEKLURY TO TREAT COVID-19 HOSPITALIZED PEDIATRIC PATIENTS UNDER 12 YRS WEIGHING AT LEAST 3.5 KG.GILEAD SCIENCES - FDA ISSUED A NEW EUA FOR USE OF VEKLURY TO TREAT COVID-19 HOSPITALIZED PEDIATRIC PATIENTS WEIGHING 3.5 KG TO LESS THAN 40 KG.

FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct 16

Oct 16 (Reuters) - FDA::FDA, IN LETTER TO GILEAD, SAYS REMDESIVIR EUA LETTER OF AUTHORIZATION, REISSUED OCTOBER 16, REMDESIVIR FOR CERTAIN HOSPITALIZED COVID-19 PATIENTS.FDA SAYS REISSUING OCT 1 LETTER TO CLARIFY THAT ALTERNATE CARE SITE MEETING CERTAIN CRITERIA IS CONSIDERED “INPATIENT HOSPITAL SETTING” FOR SCOPE OF EUA.FDA SAYS AUTHORIZING EMERGENCY USE OF VEKLURY FOR TREATMENT OF COVID-19, AS DESCRIBED IN "SCOPE OF AUTHORIZATION" SECTION OF REISSUED LETTER.FDA SAYS VEKLURY MAY BE EFFECTIVE,KNOWN & POTENTIAL BENEFITS OF VEKLURY OUTWEIGH KNOWN & POTENTIAL RISKS IN TREATMENT OF PATIENTS HOSPITALIZED WITH COVID19.

European CHMP Adopts Positive Opinion For Kite's KTE-X19 For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma

Oct 16 (Reuters) - Gilead Sciences Inc <GILD.O>::EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITE’S KTE-X19 FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA.EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITE'S KTE-X19 FOR TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA.

Gilead Sciences Issues Statement On Solidarity Trial

Oct 15 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES STATEMENT ON SOLIDARITY TRIAL.GILEAD SAYS ARE CONCERNED THAT THE DATA FROM THE OPENLABEL GLOBAL TRIAL HAVE NOT UNDERGONE RIGOROUS REVIEW.GILEAD SAYS IT IS UNCLEAR IF ANY CONCLUSIVE FINDINGS CAN BE DRAWN FROM THE STUDY RESULTS.GILEAD - WHO PREQUALIFIED REMDESIVIR, WHICH ASSURES PROCUREMENT AGENCIES SUCH AS UN THAT VEKLURY HAS MET GLOBAL STANDARDS OF QUALITY, SAFETY, EFFICACY.GILEAD SCIENCES- VEKLURY HAS NOT BEEN APPROVED BY THE U.S. FDA FOR ANY USE, AND ITS SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.

Gilead Sciences Announces Expiration Of Hart-Scott-Rodino Waiting Period For Immunomedics Tender Offer

Oct 14 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR IMMUNOMEDICS TENDER OFFER.GILEAD SCIENCES INC - EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD SATISFIES ONE OF CONDITIONS TO CONSUMMATE TENDER OFFER.GILEAD SCIENCES - REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT WITH RESPECT TO CO'S CASH TENDER OFFER FOR IMMUNOMEDICS EXPIRED AT 11:59 P.M. ON OCT 13.GILEAD SCIENCES - UNLESS TENDER OFFER IS EXTENDED, OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN TIME, ON OCTOBER 22.

Gilead Sciences Signs Joint Procurement Agreement With The European Commission For Veklury® (Remdesivir)

Oct 8 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES SIGNS JOINT PROCUREMENT AGREEMENT WITH THE EUROPEAN COMMISSION FOR VEKLURY® (REMDESIVIR).GILEAD SCIENCES INC - AGREEMENT COVERS PURCHASES OF VEKLURY OVER NEXT SIX MONTHS AND HAS OPTION TO BE EXTENDED.

EMA Starts Review After Reports Of Acute Kidney Injury In Some Covid-19 Patients Taking Remdesivir

Oct 2 (Reuters) - European Medicines Agency::EMA SAYS PRAC STARTED REVIEW OF A SAFETY SIGNAL TO ASSESS REPORTS OF ACUTE KIDNEY INJURY IN SOME PATIENTS WITH COVID-19 TAKING VEKLURY (REMDESIVIR).EMA SAYS AT THIS STAGE, IT HAS NOT BEEN DETERMINED WHETHER THERE IS A CAUSAL RELATIONSHIP BETWEEN VEKLURY AND REPORTS OF ACUTE KIDNEY INJURY.

HHS Says Gilead Anticipates Producing Sufficient Quantities Of Veklury To Meet Current Needs

Oct 1 (Reuters) - HHS::HHS SAYS GILEAD ANTICIPATES PRODUCING SUFFICIENT QUANTITIES OF VEKLURY TO MEET CURRENT NEEDS, FUTURE DEMANDS FROM ANY WAVES OF SARS-COV-2 INFECTIONS.HHS SAYS COST OF VEKLURY WILL NOT CHANGE IN TRANSITION FROM U.S. GOVERNMENT OVERSIGHT OF ALLOCATION TO DIRECT COMMERCIAL SALES.HHS SAYS HOSPITALS WILL CONTINUE TO PAY NO MORE THAN GILEAD’S WHOLESALE ACQUISITION PRICE OF VEKLURY, ABOUT $3,200 PER TREATMENT COURSE.HHS SAYS AMERISOURCEBERGEN WILL REMAIN SOLE DISTRIBUTOR OF VEKLURY THROUGH END OF YEAR TO ENSURE CONSISTENCY & CONTINUITY OF DISTRIBUTION PROCESS.HHS SAYS FEDERAL GOVERNMENT OVERSIGHT OF THE ALLOCATION OF VEKLURY IS NOT REQUIRED BECAUSE THE DRUG IS NO LONGER A SCARCE RESOURCE.HHS SAYS BEGINNING OCT 1, 2020, AMERICAN HOSPITALS CAN PURCHASE VEKLURY (REMDESIVIR) DIRECTLY FROM DRUG’S DISTRIBUTOR.HHS SAYS CURRENT SUPPLY OF VEKLURY EXCEEDS MARKET DEMAND AS EVIDENCED BY RECENT ALLOCATION NUMBERS FROM HHS’ OFFICE OF THE ASPR.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up